Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Cytokinetics (CYTK)

Cytokinetics Q1 net loss widens to $206.0 million as revenue rises to $19.4 million

Mixed Impact 3 of 5 earnings Written later

Cytokinetics reported first quarter 2026 results, with total revenues of $19.4 million versus $1.6 million a year earlier, including $4.8 million of MYQORZO net product revenue from its initial partial quarter of U.S. sales. The net loss widened to $206.0 million, or $(1.67) per share, from $161.4 million, or $(1.36) per share, as selling, general and administrative expenses rose to $104.9 million, and the company maintained its full year 2026 guidance.

Key points

  • MYQORZO net product revenue was $4.8 million, covering about 9 weeks of U.S. sales in the first quarter.
  • Revenue included an $11.9 million milestone tied to the first U.S. sale of MYQORZO under the Bayer license agreement.
  • SG&A expenses were $104.9 million versus $57.4 million a year earlier, mainly due to external costs of the MYQORZO commercial launch.
  • Cash, cash equivalents and investments were approximately $1.1 billion at March 31, 2026, down from $1.2 billion at December 31, 2025; full year 2026 combined GAAP R&D and SG&A guidance of $830 million to $870 million was maintained.

The filing

CompanyCytokinetics (CYTK)
Form8-K, current report
Filed with the SECMay 5, 2026, 4:05 PM ET
Accession number0001193125-26-206360

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:57 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.